Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
92 hedge funds and large institutions have $85.9M invested in Adverum Biotechnologies in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 42 reducing their positions, and 16 closing their positions.
669% more call options, than puts
Call options by funds: $2.47M | Put options by funds: $321K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.28% less ownership
Funds ownership: 6.72% → 6.44% (-0.28%)
6% less funds holding
Funds holding: 98 → 92 (-6)
28% less capital invested
Capital invested by funds: $119M → $85.9M (-$33M)
38% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 16
69% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.9M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$809K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$604K |
| 4 |
Invesco
Atlanta,
Georgia
|
+$381K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$354K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$10.7M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3.12M |
| 3 |
CAC
Cowen and Company
New York
|
-$1.71M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.04M |
| 5 |
Two Sigma Advisers
New York
|
-$580K |
ADVM Hedge Fund Activity: Q1 2022 in Review
92 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q1 2022, worth a combined $85.9M — down 28% from $119M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ADVM and 10 opened new positions — a net loss of 6 holders — while 42 trimmed existing stakes and 13 added.
The largest buyer was Fidelity Investments, adding an estimated $15.9M. The largest seller was RTW Investments, cutting an estimated $10.7M.
- 92 institutional investors held Adverum Biotechnologies (ADVM) as of Q1 2022, down from 98 in Q4 2021.
- Funds reported $85.9M of Adverum Biotechnologies stock for Q1 2022, down 28% quarter-over-quarter.
- 10 funds opened new Adverum Biotechnologies positions in Q1 2022 and 16 closed out, a net change of -6 holders.
- The largest Adverum Biotechnologies buyer in Q1 2022 was Fidelity Investments, an estimated $15.9M added.
- The largest Adverum Biotechnologies seller in Q1 2022 was RTW Investments, an estimated $10.7M sold.
Based on aggregated 13F filings for Q1 2022.